Top Markets
#1 QuantixAI QuantixAI +102.83%
#2 MetaDAO MetaDAO +25.19%
#3 龙虾 (Lobster) 龙虾 (Lobster) +23.59%
#4 Pons Pons +23.51%
#5 Rain Rain +21.62%
#6 Bedrock Bedrock +21.46%
#7 Ontology Gas Ontology Gas +20.86%
#8 DOG•GO•TO•THE•MOON (Runes) DOG•GO•TO•THE•MOON (Runes) +20.37%
#9 Wrapped STX (Velar) Wrapped STX (Velar) +19.56%
#10 SPX6900 SPX6900 +18.54%
Coin of the day
QuantixAI QuantixAI
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Grifols, S.A. Grifols, S.A.

Grifols, S.A.

GRF
Rang in Aktien #2537
Grifols, S.A., a Spanish company established in 1940 and headquartered in... Grifols, S.A., a Spanish company established in 1940 and headquartered in Barcelona, specializes in the comprehensive process of acquiring, manufacturing, preparing, and distributing therapeutic products, with a primary focus on those derived from plasma. The company operates through several key divisions: Bioscience, Hospital, Diagnostic, and Bio Supplies, among others. The Bioscience division is dedicated to the research, development, production, and commercialization of plasma-derived medicines and other cutting-edge solutions. These are designed to treat individuals suffering from chronic, rare, widespread, and life-threatening medical conditions, with its product portfolio including immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division supplies a range of non-biological pharmaceutical products, clinical nutrition items, intravenous (IV) therapy solutions, and various medical devices and supplies. Grifols' Diagnostic division develops and markets advanced diagnostic tools that support healthcare professionals across the entire patient care continuum, from prevention and screening to accurate diagnosis, prognosis, and ongoing disease and treatment monitoring. Finally, the Bio Supplies division provides essential biological materials for life-science research, clinical trials, and the manufacturing of both pharmaceutical and diagnostic goods. Collectively, Grifols' offerings enable healthcare providers to effectively diagnose and treat a broad spectrum of medical conditions, such as hemophilia, various immune deficiencies, and infectious diseases. Its diverse client base includes public and private sector organizations, wholesalers, distributors, group purchasing organizations (GPOs), blood banks, hospitals, care institutions, and national health systems. Grifols also maintains a technology collaboration agreement with Mondragon.
Aktienkurs
$11.91
Marktkapitalisierung
$8.11B
Veränderung (1 Tag)
1.67%
Veränderung (1 Jahr)
-16.23%
Land
ES
Handel Grifols, S.A. (GRF)

Kategorie

Healthcare
Aktien-Split-Historie für Grifols, S.A. (GRF)
Die Aktie Grifols, S.A. (Symbol: GRF) durchlief insgesamt 0 Aktiensplits.
Der letzte Aktiensplit fand am Aug 25, 2026 statt.
Eine GRF-Aktie, die vor dem Aug 25, 2026 gekauft wurde, entspricht heute 0 GRF-Aktien.
Liste der Aktiensplits
Jahr Aktien-Split Multiplikator Kumulierter Multiplikator
Nicht genügend Daten für die angegebenen Daten.
Aktiensplits ähnlicher Unternehmen oder Wettbewerber
Unternehmen Anzahl der Aktiensplits Kumulierter Multiplikator Land
Eli Lilly and Company Eli Lilly and Company
Eli Lilly and Company
LLY.US
 4 x15
US
Johnson & Johnson Johnson & Johnson
Johnson & Johnson
JNJ.US
 7 x432
US
AbbVie Inc. AbbVie Inc.
AbbVie Inc.
ABBV.US
 0 -
US
Roche Holding AG Roche Holding AG
Roche Holding AG
RO.SW
 2 x10000
CH
Merck & Co., Inc. Merck & Co., Inc.
Merck & Co., Inc.
MRK.US
 7 x226
US